ACS DOBFAR
GenericsACS DOBFAR is a generic drug manufacturer focused on Infectious Disease, Dermatology.
ACS DOBFAR's Key Drugs
ACS DOBFAR's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
ACS DOBFAR's Recent FDA Approvals
New NDA/BLA approvals for ACS DOBFAR over the last two years — novel drugs only, excluding generics and label supplements.
ACS DOBFAR's Therapeutic Areas
ACS DOBFAR's approved drugs and pipeline span 2 therapeutic areas, led by Infectious Disease and Dermatology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ACS DOBFAR's Top Competitors
ACS DOBFAR's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and B BRAUN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ACS DOBFAR Pipeline Snapshot
Active clinical trials for ACS DOBFAR across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (1)
Company Info
- First Approval
- 1973-11-02
- Latest
- 2026-05-20
- Applications
- 14